stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) Revenue growth
Tango Therapeutics, Inc.'s revenue growth over the twelve months to 31 December 2025 was 48.3%. Over the past ten years it has ranged from −79.3% (fiscal 2020) to 383.8% (fiscal 2021); the current reading is higher than 83% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 48.3% | 33.12 |
| FY2024 | 15.2% | (31.76) |
| FY2023 | 46.9% | 79.82 |
| FY2022 | −32.9% | (416.72) |
| FY2021 | 383.8% | 463.16 |
| FY2020 | −79.3% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Dec 2025 | −100.0% | (463.61) |
| Sep 2025 | 363.6% | 447.60 |
| Jun 2025 | −84.0% | (67.32) |
| Mar 2025 | −16.7% | 7.54 |
| 13 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| ABCL AbCellera Biologics Inc. compare | 101.3% |
| IOVA Iovance Biotherapeutics, Inc. compare | 51.3% |
| TNGX Tango Therapeutics, Inc. | 48.3% |
| ACAD ACADIA Pharmaceuticals Inc. compare | 14.8% |
| XENE Xenon Pharmaceuticals Inc. compare | −8.15% |
| RLAY Relay Therapeutics, Inc. compare | −74.3% |
| PBLS Parabilis Medicines, Inc. compare | — |
| EWTX Edgewise Therapeutics, Inc. compare | — |
| IRON Disc Medicine, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement